5 completed, 4 unknown, 3 recruiting, 3 terminated. 7 Phase 2, 5 Phase 1, 3 Not applicable, 1 Phase 4.
Follow Biological: new trials by email Literature Review of Biological trials Research Report on Biological
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous PRP Versus Triamcinolone Acetate in Patients With Oral Submucous Fibrosis Autologous Platelet-Rich Plasma, Triamcinolone Acetate - Oral Submucous Fibrosis | Not applicable | Not yet recruiting | Allama Iqbal Medical College | 40 | 2026-11-01 | 2026-11-03 |
| Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies Biological samples, Biological - Bone Disorder | Recruiting | University Hospital, Toulouse | 350 | 2024-09-16 | 2026-06-05 | |
| Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A Gene therapy, Biological - Hemophilia A | Phase 1 | Not yet recruiting | Expression Therapeutics, LLC | 7 | 2024-09-01 | 2024-02-20 |
| A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) AAV2-GDNF gene therapy, control surgery - Parkinson Disease | Phase 2 | Active not recruiting | AskBio Inc | 59 | 2024-06-11 | 2026-11-05 |
| BenRalizumab Effect on Airway Remodeling in Severe asTHma Benralizumab 30 mg/ml - Asthma; Eosinophilic, Airway Remodeling | Phase 4 | Completed | Aristotle University Of Thessaloniki | 36 | 2024-03-01 | 2026-10-28 |
| Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial Peripheral Intravenous (IV) infusion of LMSCs - Metabolic Disease, Endothelial Dysfunction | Phase 2 | Withdrawn | Longeveron Inc. | 2023-12-01 | 2023-02-16 | |
| Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia Biological - Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse | Not applicable | Unknown | Aibin Liang，MD，Ph.D. | 12 | 2023-04-12 | 2023-06-08 |
| Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors Biological - Refractory/Relapse Neuroblastoma, Pediatric Solid Tumors | Phase 1 | Recruiting | Kyushu University | 61 | 2022-10-26 | 2026-08-07 |
| Relationship Between Fungal Colonization and Severe Bronchopulmonary Dysplasia biological - Bronchopulmonary Dysplasia, Extreme Prematurity | Completed | Centre Hospitalier Sud Francilien | 153 | 2022-03-21 | 2024-11-26 | |
| Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC Biological - Cell Therapy, NSCLC | Phase 1 / Phase 2 | Terminated | GAIA BioMedicine Inc. | 22 | 2021-12-01 | 2026-09-03 |
| Stress in Pregnancy During the Covid19 Pandemic and Impact on the Newborn Neurodevelopment Severity of infection, time of infection., Mental health assessment, biological - Covid19 and Pregnancy | Unknown | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 1000 | 2021-08-01 | 2024-04-12 | |
| Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease Biological - Severe COVID-19 Disease | Phase 2 | Completed | Hospital Central Militar | 150 | 2020-06-23 | 2021-05-10 |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. NZV930, PDR001, NIR178 - Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC) | Phase 1 | Terminated | Novartis Pharmaceuticals | 127 | 2018-07-18 | 2024-12-13 |
| Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO Biological - Shock, Cardiogenic, Extra-Corporeal-Life-Support ( ECLS) | Not applicable | Completed | Central Hospital, Nancy, France | 48 | 2017-10-10 | 2023-04-19 |
| COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk) Biological - Crohn's Disease | Completed | University Hospital, Lille | 214 | 2016-05-09 | 2025-12-16 | |
| Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy Biological - Treatment of Type I Diabetes Mellitus. | Phase 1 / Phase 2 | Unknown | DiaVacs, Inc. | 90 | 2013-10-01 | 2013-10-23 |
| Collagenase in the Treatment of Cellulite Collagenase, Biological - Cellulite | Phase 2 | Unknown | Stony Brook University | 20 | 2013-02-01 | 2012-12-12 |
| Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary Biological, Tissular, Quality of life - Malignant Melanoma | Recruiting | Assistance Publique - Hôpitaux de Paris | 6000 | 2013-02-01 | 2025-02-11 | |
| A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 | Terminated | Pfizer | 679 | 2009-11-17 | 2021-05-13 |
Airway Remodeling (1) · Asthma (1) · Autonomic Nervous System Diseases (1) · Bone Diseases (1) · Bronchopulmonary Dysplasia (1) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Cellulite (1) · Crohn Disease (1) · Dysbiosis (1) · Hemophilia A (1) · Inflammation (1) · Melanoma (1) · Metabolic Diseases (1)
Aibin Liang，MD，Ph.D. (1) · Allama Iqbal Medical College (1) · Aristotle University Of Thessaloniki (1) · AskBio Inc (1) · Assistance Publique - Hôpitaux de Paris (1) · Central Hospital, Nancy, France (1) · Centre Hospitalier Sud Francilien (1) · DiaVacs, Inc. (1) · Expression Therapeutics, LLC (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · GAIA BioMedicine Inc. (1) · Hospital Central Militar (1) · Kyushu University (1) · Longeveron Inc. (1) · Novartis Pharmaceuticals (1)
France (5) · United States (5) · Japan (3) · Spain (2) · United Kingdom (2) · Australia (1) · Canada (1) · China (1) · Germany (1) · Greece (1) · Mexico (1) · Pakistan (1) · Poland (1) · Singapore (1)
Aibin Liang (1) · Alexander B Dagum, MD (1) · Anthony Oliva, PhD (1) · Antoine Kimmoun, MD (1) · Carmen G Torres, MD (1) · Celeste Lebbe, MD, PhD (1) · Corinne Gower-Rousseau, MD, PhD (1) · Gaelle Quereux, MD, PhD (1) · Kalliopi Domvri, Dr (1) · Marie A Badalamente, PhD (1) · Yoshikazu Yonemitsu, MD, PhD (1)
PMID 12045120, PMID 21037369, PMID 28461289, PMID 29221581, PMID 31798645, PMID 35288462, PMID 37343842
2018 (1)